---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-25-000156"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:00:59.119277+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xeris Q3 product revenue $74M (+40% YoY); raises FY2025 guidance to $285-290M

## Summary
- Total product revenue $74.1M, up 40% YoY; total revenue $74.4M (+37% YoY).
- Recorlev revenue $37.0M (+109% YoY); Gvoke $25.2M (+10%); Keveyis $11.9M (-2%).
- Net income $0.6M vs net loss $15.7M in Q3 2024; adjusted EBITDA $17.4M.
- FY2025 total revenue guidance raised to $285-290M from $280-290M, implying ~42% growth at midpoint.
- CEO cites record quarter driven by increased patient demand across all three products.

## SEC filing metadata
- accession: 0001867096-25-000156
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000156/0001867096-25-000156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000156/xers-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-25-000156
- JSON: https://secwatch.observer/filing/0001867096-25-000156.json
- Plain text: https://secwatch.observer/filing/0001867096-25-000156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.